Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA4 | P22748 | 2/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.56 |
| ▸ | LIG1 | P18858 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL27570483 | 0.96 | HPGD (0.76) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL21192456 | 0.96 | KDM4E (0.83) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL30933946 | 0.96 | KDM4E (0.83) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL8986246 | 0.94 | KDM4E (0.80) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL31186668 | 0.91 | KDM4E (0.91) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL5450889 | 0.89 | KDM4E (0.95) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL6249450 | 0.89 | KDM4E (0.95) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL23795260 | 0.87 | HPGD (0.83) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL31140000 | 0.87 | HPGD (0.83) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL31140005 | 0.87 | HPGD (0.83) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1150718-A1 | CONJUGATES OF LIPIDS AND ANTIMICROBIAL OR ANTINEOPLASTIC DRUGS | OREGON HEALTH SCIENCES UNIVERSITY (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000033883-A1 | COVALENT POLAR LIPID CONJUGATES WITH ANTIMICROBIAL AND ANTINEOPLASTIC DRUGS FOR TARGETING TO BIOLOGICAL PROTECTED SITES | OREGON HEALTH SCIENCES UNIVERSITY (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000033884-A1 | CONJUGATES OF LIPIDS AND ANTIMICROBIAL OR ANTINEOPLASTIC DRUGS | OREGON HEALTH SCIENCES UNIVERSITY (US) | 2000-06-15 | — | — | WO | disclosed |